GO
Loading...

Medicine

More

  • The NYT, JNJ & That Tricky "Billion" Monday, 5 Jan 2009 | 4:01 PM ET

    We all make mistakes. Gosh knows I've made more than a few. And a part of me hesitates to call attention to this one. I mean, you know what they say about paybacks and karma. But this one is too good a doozy to let pass.

  • Pfizer Rekindling Deal Talk? Monday, 5 Jan 2009 | 11:25 AM ET

    The "Financial Times" apparently got a one-on-one interview with Pfizer Chairman and CEO Jeff Kindler and is playing up what he said with the headline, "Pfizer eyes merger deal with large rival."

  • Glaxo, Merck & Pfizer: Your Emails Tuesday, 23 Dec 2008 | 1:16 PM ET

    As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.

  • Vertex's $75,000 Question Friday, 19 Dec 2008 | 3:14 PM ET

    Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.

  • Pfizer's 40 Year Run Of Hiking Dividend Ends Tuesday, 16 Dec 2008 | 10:44 AM ET

    For months now several analysts have been pointing out that despite big pharma's many problems some of the companies still pay healthy dividends. And when T-bills are offering next to nothing, a solid dividend yield in these rough and tumble times is a good thing.

  • Eli Lilly's Lechleiter: "Ludicrous" Stock Price Thursday, 11 Dec 2008 | 9:59 AM ET

    CEOs of big drug companies are rarely, if ever, publicly candid about the price of their stock. You usually get the boilerplate line about how they manage the business and the market will do whatever.

  • Merck Yesterday, Lilly Tomorrow Wednesday, 10 Dec 2008 | 11:25 AM ET

    Analysts have a one-day respite between two major pharma R & D days and they're using it to size up Merck's update yesterday and to set expectations for Eli Lilly's briefing tomorrow.

  • Merck Update Tuesday, 9 Dec 2008 | 2:20 PM ET

    I wrote this morning's post from the Merck analyst meeting before sitting down for my exclusive interview with Exec Veep Ken Frazier. So, I had to pass along this fresh anecdote that illustrates even more how far this drug company and its people have come.

  • Merck's Pipeline And Press Progress Tuesday, 9 Dec 2008 | 1:38 PM ET

    Sitting here at Merck's annual drug research and development for the Street in the media room at the company's headquarters in central New Jersey. This year, for the first time, MRK is allowing reporters into the actual meeting room with the 300 or so analysts and investors

  • Is Merck A Drug Bellwether? Thursday, 4 Dec 2008 | 11:24 AM ET

    Earlier this week UBS pharmaceutical analyst Roopesh Patel put out a big 2009 sector outlook research note claiming, "So far, the global economic slowdown has had no noticeable impact — a) U.S. weekly and monthly U.S. prescription trends are stable; b) there also is no meaningfully cautionary commentary from any of the companies...." Well, he might have spoken too soon.

  • Predictions: 9 For '09 In Pharma Monday, 1 Dec 2008 | 2:00 PM ET

    Look for M&A activity—big and small—a pair of breakthrough drugs and the prospect of government price controls.

  • Johnson & Johnson Is Latest FDA Casualty Wednesday, 26 Nov 2008 | 11:36 AM ET

    Does the Food and Drug Administration approve drugs anymore? Or are we seeing the lame-duck leadership at the agency punt any action over to the next administration?

  • Pharma Updates And What You Need To Know Monday, 24 Nov 2008 | 9:15 AM ET

    As the market remains focused on Citi and the President-elect's midday cabinet announcement there are a few newsworthy things going on in biopharmaland.

  • Daschle's Dollars From Lawyers, Not Pharma Wednesday, 19 Nov 2008 | 4:21 PM ET
    Tom Daschle

    Over the course of his congressional career the CRP shows that not a single drug company ever broke onto Daschle's top-20 list of contributors. The only healthcare-related firm that pops up is Invacare.

  • Carl Icahn: Can He Come To Amylin's Rescue? Monday, 17 Nov 2008 | 11:09 AM ET
    Carl Icahn

    Wall Street has essentially thrown in the towel lately on Amylin Pharmaceuticals. The shares have plummeted from nearly $30 just three months ago to around $7 today.

  • Merck's Marketing Challenge: Gardasil For Guys Thursday, 13 Nov 2008 | 4:16 PM ET

    How in the world is Merck gonna rebrand a product it has spent so much time, effort and money gearing toward females so that males will use it, too? I'm not sure, but it'll be interesting to watch if or when MRK wins Food and Drug Administration approval of Gardasil for boys/young men.

  • Pharma And The Financial Crisis Thursday, 13 Nov 2008 | 11:11 AM ET
    Big Pharma

    Big pharma's got big problems. That should not come as news to anyone who works for, follows or invests in the industry.

  • "Boning Up" On Amgen's D-mab Friday, 7 Nov 2008 | 12:05 PM ET
    AMGEN

    While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one.

  • FDA Commissioner: Betting Starts On Who Obama Will Pick Wednesday, 5 Nov 2008 | 12:20 PM ET
    Barack Obama

    Even before the results of the election were official there was already speculation in the blogosphere about who might become the next Commissioner of the Food and Drug Administration under a President Obama.

  • Athletes And The Weapons To Fight The "Superbug" Friday, 31 Oct 2008 | 1:24 PM ET

    I’m sure you’ve seen all the stories regarding athletes and staph infections more technically known as MRSA. Although the information each time has been sketchy, the names Kellen Winslow, Tom Brady and Peyton Manning have become associated with it in recent weeks.